Satoshi Tamada
About
Satoshi Tamada is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology.
According to data from OpenAlex, Satoshi Tamada has authored 69 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 21 papers in Molecular Biology and 20 papers in Oncology. Recurrent topics in Satoshi Tamada's work include Renal cell carcinoma treatment (24 papers), Prostate Cancer Treatment and Research (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Satoshi Tamada is often cited by papers focused on Renal cell carcinoma treatment (24 papers), Prostate Cancer Treatment and Research (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Satoshi Tamada collaborates with scholars based in Japan, United States and United Kingdom. Satoshi Tamada's co-authors include Tatsuya Nakatani, Katsuyuki Miura, Brian I. Rini, Elizabeth R. Plimack, Bohuslav Melichar, Sérgio Jobim Azevedo, Denis Soulières, Frédéric Pouliot, Thomas Powles and Rustem Gafanov and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.
In The Last Decade
Satoshi Tamada
66 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Satoshi Tamada Japan | 22 | 982 | 658 | 587 | 377 | 278 | 69 | 1.7k | ||
| Kazuyuki Numakura Japan | 22 | 660 0.7× | 447 0.7× | 450 0.8× | 304 0.8× | 389 1.4× | 152 | 1.7k | ||
| Sri Harsha Tella United States | 23 | 414 0.4× | 967 1.5× | 818 1.4× | 287 0.8× | 658 2.4× | 95 | 2.5k | ||
| Badar M. Mian United States | 21 | 840 0.9× | 521 0.8× | 718 1.2× | 340 0.9× | 390 1.4× | 60 | 1.9k | ||
| Edwin Herrmann Germany | 21 | 653 0.7× | 396 0.6× | 674 1.1× | 506 1.3× | 297 1.1× | 47 | 1.5k | ||
| Daniel Keizman Israel | 23 | 1.0k 1.0× | 678 1.0× | 320 0.5× | 332 0.9× | 291 1.0× | 98 | 1.7k | ||
| Jie Jin China | 24 | 849 0.9× | 375 0.6× | 676 1.2× | 310 0.8× | 296 1.1× | 103 | 1.7k | ||
| Klaus Baumann Germany | 22 | 421 0.4× | 1.0k 1.6× | 378 0.6× | 247 0.7× | 319 1.1× | 84 | 2.2k | ||
| Eugene R. Ahn United States | 22 | 346 0.4× | 604 0.9× | 443 0.8× | 331 0.9× | 189 0.7× | 78 | 1.6k | ||
| Ryuichi Mizuno Japan | 28 | 1.2k 1.2× | 926 1.4× | 1.1k 1.8× | 526 1.4× | 509 1.8× | 205 | 2.6k | ||
| F J G M Kubben Netherlands | 17 | 829 0.8× | 1.2k 1.8× | 479 0.8× | 416 1.1× | 952 3.4× | 24 | 2.0k |
Countries citing papers authored by Satoshi Tamada
Since
Specialization
Citations
This map shows the geographic impact of Satoshi Tamada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Tamada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Tamada more than expected).
Fields of papers citing papers by Satoshi Tamada
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Satoshi Tamada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Tamada. The network helps show where Satoshi Tamada may publish in the future.
Co-authorship network of co-authors of Satoshi Tamada
This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Tamada. A scholar is included among the top collaborators of Satoshi Tamada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Tamada. Satoshi Tamada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kondoh, Chihiro, Woo Kyun Bae, Satoshi Tamada, et al.. (2025). First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia. Japanese Journal of Clinical Oncology. 55(4). 406–413.
2.
Nakaigawa, Noboru, Yoshihiko Tomita, Satoshi Tamada, et al.. (2023). Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. International Journal of Clinical Oncology. 28(3). 416–426.
3.
Tamada, Satoshi, Masahiro Nozawa, Ryuichi Mizuno, et al.. (2022). Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study. International Journal of Clinical Oncology. 28(2). 289–298.
4.
Tamada, Satoshi, Chihiro Kondoh, Nobuaki Matsubara, et al.. (2021). Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study. International Journal of Clinical Oncology. 27(1). 154–164.
5.
Kondoh, Chihiro, Woo Kyun Bae, Satoshi Tamada, et al.. (2020). 200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia. Annals of Oncology. 31. S1319–S1319.
6.
Nozawa, Masahiro, Satoshi Tamada, Kojiro Ohba, et al.. (2020). 729P Prognostic value of PD-L1 status in the primary lesion as a risk factor for developing metastatic disease in localized renal cell carcinoma: A subgroup analysis of the ARCHERY study. Annals of Oncology. 31. S570–S571.
7.
Tomita, Yoshihiko, Katsunori Tatsugami, Noboru Nakaigawa, et al.. (2020). Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients. International Journal of Urology. 27(11). 952–959.
8.
Iguchi, Taro, et al.. (2019). Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). BMC Cancer. 19(1). 339–339.
9.
Moriyama, Hiroyuki, Mariko Moriyama, Toshiyuki Ozawa, et al.. (2018). Notch Signaling Enhances Stemness by Regulating Metabolic Pathways Through Modifying p53, NF-κB, and HIF-1α. Stem Cells and Development. 27(13). 935–947.
10.
Iguchi, Taro, et al.. (2018). Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents. Cancer Management and Research. Volume 10. 2977–2982.
11.
Kato, Minoru, Takeshi Yamasaki, Taro Iguchi, et al.. (2018). Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma. International Journal of Clinical Oncology. 23(5). 944–950.
12.
Iguchi, Taro, Ching Y. Wang, Nicolas Barry Delongchamps, et al.. (2015). Association of MnSOD AA Genotype with the Progression of Prostate Cancer. PLoS ONE. 10(7). e0131325–e0131325.
13.
Kato, Minoru, Shotaro Yamano, Anna Kakehashi, et al.. (2012). DDX 39 acts as a suppressor of invasion for bladder cancer. Cancer Science. 103(7). 1363–1369.
14.
Tanaka, Tomoaki, et al.. (2011). Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan. BMC Urology. 11(1). 11–11.
15.
Hosono, Tatsuya, et al.. (2009). Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells. Prostate Cancer and Prostatic Diseases. 12(4). 375–381.
16.
Kawashima, Hidenori, Tomoaki Tanaka, Katsuyuki Kuratsukuri, et al.. (2007). Palliative Treatment of Bone Metastases in Hormone-Refractory Prostate Cancer: Effects of Pamidronate on the Carboxyterminal Telopeptide of Type-I Collagen Level in Patients with Increasing Prostate-Specific Antigen Levels. Urologia Internationalis. 78(4). 345–350.
17.
Kuwabara, Nobuyuki, Satoshi Tamada, Tomoaki Iwai, et al.. (2006). Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology. 67(2). 440–446.
18.
Tamada, Satoshi, Tatsuya Nakatani, Toshihiro Asai, et al.. (2003). Inhibition of nuclear factor-κB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. Kidney International. 63(1). 306–314.
19.
Nakatani, Tatsuya, Satoshi Tamada, Toshihiro Asai, et al.. (2002). Role of Renin-Angiotensin System and Nuclear Factor-κB in the Obstructed Kidney of Rats With Unilateral Ureteral Obstruction. The Japanese Journal of Pharmacology. 90(4). 361–364.
20.
Miura, Katsuyuki, Tatsuya Nakatani, Toshihiro Asai, et al.. (2002). ROLE OF HYPOMAGNESEMIA IN CHRONIC CYCLOSPORINE NEPHROPATHY1. Transplantation. 73(3). 340–347.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kazuyuki Numakura Breakdown of academic impact, for papers by Sri Harsha Tella Breakdown of academic impact, for papers by Badar M. Mian Breakdown of academic impact, for papers by Edwin Herrmann Breakdown of academic impact, for papers by Daniel Keizman Breakdown of academic impact, for papers by Jie Jin Breakdown of academic impact, for papers by Klaus Baumann Breakdown of academic impact, for papers by Eugene R. Ahn Breakdown of academic impact, for papers by Ryuichi Mizuno Breakdown of academic impact, for papers by F J G M Kubben